newsfilter
← Latest News
GlobeNewswire·

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

  • Tenax Therapeutics, Inc. announced that President & CEO Chris Giordano will present at the 2026 Cantor Global Healthcare Conference.
  • The presentation is scheduled for Wednesday, September 9, 2026, at 8:35 a.m. ET.
  • A live & archived webcast of the event will be available on the company's investor relations webpage.
  • Tenax is a Phase 3 development-stage pharmaceutical company focused on novel cardiopulmonary therapies.
  • The company holds global rights to develop & commercialize levosimendan for PH-HFpEF, a prevalent form of pulmonary hypertension with no approved treatments to date.
  • Tenax's common stock trades on The Nasdaq Stock Market under the symbol "TENX".
  • Investor & media inquiries can be directed to Argot Partners at tenax@argotpartners.com.